Structural and functional properties of platelet-derived growth factor and stem cell factor receptors

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 8, 2013, Pages

  Heldin, Carl Henrik ^a   Lennartsson, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANTAGONISTS AND INHIBITORS; DIMERIZATION; EMBRYO DEVELOPMENT; ENZYME SPECIFICITY; GENETICS; HOMEOSTASIS; METABOLISM; MUTATION; NEOPLASM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

DIMERIZATION; EMBRYONIC DEVELOPMENT; HOMEOSTASIS; MEMBRANE PROTEINS; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, COLONY-STIMULATING FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84881083630     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009100     Document Type: Article

References (181)

1. Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, Berrozpe G, Kissel H, Tucker CM, Manova K, Moore MA, et al. 2004. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med 199: 867-878.
2. Andrae J, Gallini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
3. Antonescu CR. 2011. The GIST paradigm: Lessons for other kinase-driven cancers. J Pathol 223: 251-261.
4. Arai H, Ueno T, Tangoku A, Yoshino S, Abe T, Kawauchi S, Oga A, Furuya T, Oka M, Sasaki K. 2003. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: Comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet 146: 16-21.
5. Ashida A, Takata M, Murata H, Kido K, Saida T. 2009. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124: 862-868.
6. Bae YS, Sung J-Y, Kim O-S, Kim YJ, Hur KC, Kazlauskas A, Rhee SG. 2000. Platelet-derived growth factor-induced H2O2 production requires the activation of phosphatidy-linositol 3-kinase. J Biol Chem 275: 10527-10531.
7. Ball SG, Shuttleworth CA, Kielty CM. 2007. Vascular endo-thelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 177: 489-500.
8. Baxter RM, Secrist JP, Vaillancourt RR, Kazlauskas A. 1998. Full activation of the platelet-derived growth factor b-receptor kinase involves multiple events. J Biol Chem 273: 17050-17055.
9. Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P. 2004. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 279: 12249-12259.
10. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD. 1986. A new acute transforming feline retro-virus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320: 415-421.
11. Bjarnegård M, Enge M, Norlin J, Gustafsdottir S, Fredriks-son S, Abramsson A, Takemoto M, Gustafsson E, Fässler R, Betsholtz C. 2004. Endothelium-specific ablation of PDGFB leadsto pericyte loss and glomerular, cardiac and placental abnormalities. Development 131: 1847-1857.
12. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411: 355-365.
13. Blume-Jensen P, Siegbahn A, Stabel S, Heldin C-H, Rönn-strand L. 1993. Increased Kit/SCF receptor induced mi-togenicity but abolished cell motility after inhibition of protein kinase C. EMBO J 12: 4199-4209.
14. Blume-Jensen P, Wernstedt C, Heldin C-H, Rönnstrand L. 1995. Identification of the major phosphorylation sites for protein kinase C in Kit/stem cell factor receptor in vitro and in intact cells. J Biol Chem 270: 14192-14200.
15. Blume-Jensen P, Janknecht R, Hunter T. 1998. The Kit receptor promotes cell survival via activation ofPI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8: 779-782.
16. 0-kinase is essential for male fertility. Nat Genet 24: 157-162.
17. Bonner JC. 2004. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15: 255- 273.
18. Boström H, Willetts K, Pekny M, Levéen P, Lindahl P, Hed-strand H, Pekna M, Hellström M, Gebre-Medhin S, Schalling M, et al. 1996. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85: 863-873.
19. Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG, Herz J. 2002. Platelet-derived growth factor mediates ty-rosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in cav-eolae. J Biol Chem 277: 15507-15513.
20. Brennan J, Tilmann C, Capel B. 2003. PDGFR-a mediates testis cord organization and fetal Leydig cell development in the XY gonad. Genes Dev 17: 800-810.
21. Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, Richardson WD. 1998. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 20: 869-882.
22. Caruana G, Cambareri AC, Ashman LK. 1999. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 18: 5573-5581.
23. Catena R, Luis-Ravelo D, Anton I, Zandueta C, Salazar-Co-locho P, Larzabal L, Calvo A, Lecanda F. 2010. PDGFR signaling blockadeinmarrow stroma impairs lung cancer bone metastasis. Cancer Res 71: 164-174.
24. Chen H, Gu X, Liu Y, Wang J, Wirt SE, Bottino R, Schorle H, Sage J, Kim SK. 2011. PDGF signalling controls age-dependent proliferation in pancreatic b-cells. Nature 478: 349-355.
25. Chiara F, Bishayee S, Heldin C-H, Demoulin J-B. 2004. Autoinhibition of the platelet-derived growth factor b receptor tyrosine kinase by its C-terminal tail. J Biol Chem 279: 19732-19738.
26. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, PatiS, et al. 2010. Cardiomyocyte PDGFR-b signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 120: 472-484.
27. Clarke ID, Dirks PB. 2003. A human brain tumor-derived PDGFR-a deletion mutant is transforming. Oncogene 22: 722-733.
28. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idio-pathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
29. Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE. 1993. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 82: 1151-1158.
30. Curtin JA, Busam K, Pinkel D, Bastian BC. 2006. Somatic activation ofKITin distinct sub types of melanoma.J Clin Oncol 24: 4340-4346.
31. Dance M, Montagner A, Salles JP, Yart A, Raynal P. 2008. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 20: 453-459.
32. Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Freneaux P, Livartowski A, Pouillart P, Poupon MF. 2005. In vivo efficacy of STI571 in xeno-grafted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 113: 849-856.
33. Demetri GD. 2011. Differential properties of current tyro-sine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 38: S10-S19.
34. {thorn} exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF. Bio-chem J 376: 505-510.
35. DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW, Diehl W, English JM, Wu JC. 2010. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in su-nitinib resistance. J Biochem 147: 601-609.
36. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306-1312.
37. Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A. 2005. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by a platelet-derived growth factor receptor. Oncogene 24: 6848-6854.
38. Easty DJ, Bennett DC. 2000. Protein tyrosine kinases in malignant melanoma. Melanoma Res 10: 401-411.
39. Ekman S, Rupp Thuresson E, Heldin C-H, Rönnstrand L. 1999. Increased mitogenicity of an ab heterodimeric PDGF receptor complex correlates with lack of RasGAP binding. Oncogene 18: 2481-2488.
40. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann WK, et al. 2011. Novel imatinib-sensitive PDGFRA-acti-vating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117: 2935-2943.
41. Eriksson A, Siegbahn A, Westermark B, Heldin C-H, Claesson-Welsh L. 1992. PDGF a- and b-receptors activate unique and common signal transduction pathways. EMBO J 11: 543-550.
42. Faraone D, Aguzzi MS, Ragone G, Russo K, Capogrossi MC, Facchiano A. 2006. Heterodimerization of FGF-receptor 1 and PDGF-receptor-a: A novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 107: 1896-1902.
43. Fischer B, Marinov M, Arcaro A. 2007. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far? Cancer Treat Rev 33: 391-406.
44. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU. 1992. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-4553.
45. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. 2002. Juxta-membrane mutant V560GKit is more sensitive to Imati-nib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1: 1115-1124.
46. Fruttiger M, Calver AR, Krüger WH, Mudhar HS, Micha-lovich D, Takakura N, Nishikawa SI, Richardson WD. 1996. PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron 17: 1117-1131.
47. Fruttiger M, Calver AR, Richardson WD. 2000. Platelet-derived growth factor is constitutively secreted from neuronal cell bodies but not from axons. Curr Biol 10: 1283-1286.
48. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lund-kvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, et al. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161: 1163-1177.
49. Gnessi L, Basciani S, Mariani S, Arizzi M, Spera G, Wang C, Bondjers C, Karlsson L, Betsholtz C. 2000. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice.JCell Biol 149: 1019-1026.
50. Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307-316.
51. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H, et al. 2006. A crucial function of PDGF in TGF-b-medi-ated cancer progression of hepatocytes. Oncogene 25: 3170-3185.
52. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R, 2003. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci 100: 7830-7835.
53. Hamilton TG, Klinghoffer RA, Corrin PD, Soriano P. 2003. Evolutionary divergence ofplatelet-derived growth factor a receptor signaling mechanisms. Mol Cell Biol 23: 4013-4025.
54. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
55. Heidaran MA, Pierce JH, Jensen RA, MatsuiT, Aaronson SA. 1990. Chimeric a- and b-platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the a-PDGF receptor that determine PDGF-AA binding specificity. J Biol Chem 265: 18741-18744.
56. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710.
57. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, et al. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109: 625-637.
58. Heldin C-H, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
59. Heldin C-H, Wasteson A, Westermark B. 1982. Interaction of platelet-derived growth factor with its fibroblast receptor. Demonstration of ligand degradation and receptor modulation. J Biol Chem 257: 4216-4221.
60. Heldin C-H, Ostman A, Rönnstrand L. 1998. Signal trans-duction via platelet-derived rowth factor receptors. Bio-chim Biophys Acta 1378: F79-F113.
61. Heldin C-H, Rubin K, Pietras K, Ostman A. 2004. High interstitial fluid pressure-An obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
62. Hellberg C, Schmees C, Karlsson S, Ahgren A, Heldin C-H. 2009. Activation of protein kinase C a is necessary for sorting the PDGF b-receptor to Rab4a-dependent recycling. Mol Biol Cell 20: 2856-2863.
63. Hellström M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. 1999. Role of PDGF-B and PDGFR-b in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126: 3047-3055.
64. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, Nistér M. 1992. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219.
65. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H. 1991. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296.
66. Hoch RV, Soriano P. 2003. Roles of PDGF in animal development. Development 130: 4769-4784.
67. Hong L, Munugalavadla V, Kapur R. 2004. c-Kit-mediated overlapping and unique functional and biochemical outcomes via diverse signaling pathways. Mol Cell Biol 24: 1401-1410.
68. Huang EJ, Nocka KH, Buck J, Besmer P. 1992. Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 3: 349-362.
69. Hubbard SR. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581.
70. Hubbard SR. 2004. Juxtamembrane autoinhibition in receptor tyrosine kinases. NatRev Mol Cell Biol 5: 464-471.
71. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. 1995. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373: 347-349.
72. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishi-kawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD. 1991. Expression and functional role of the proto-onco-gene c-kit in acute myeloblastic leukemia cells. Blood 78: 2962-2968.
73. Irusta PM, Luo Y, Bakht O, Lai CC, Smith SO, DiMaio D. 2002. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor b receptor. J Biol Chem 277: 38627-38634.
74. Jackman DM, Johnson BE. 2005. Small-cell lung cancer. Lancet 366: 1385-1396.
75. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, et al. 2005. Blockade of platelet-derived growth factor receptor-b by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23: 973-981.
76. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N. 2003. Expression profiling of epithelial plasticity in tumor progression. Oncogene 22: 7155-7169.
77. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S. 2006. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116: 1561-1570.
78. Jin K, Mao XO, Sun Y, Xie L, Greenberg DA. 2002. Stem cell factor stimulates neurogenesis in vitro and in vivo. J Clin Invest 110: 311-319.
79. Karlsson L, Bondjers C, Betsholtz C. 1999. Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle. Development 126: 2611-2621.
80. Karlsson L, Lindahl P, Heath JK, Betsholtz C. 2000. Abnormal gastrointestinal development in PDGF-A and PDGFR-a deficient mice implicates a novel mesenchy-mal structure with putative instructive propertiesinvillus morphogenesis. Development 127: 3457-3466.
81. Karlsson S, Kowanetz K, Sandin A, Persson C, Ostman A, Heldin C-H, Hellberg C. 2006. Loss of T-cell protein tyrosine phosphatase induces recycling of the platelet-derived growth factor (PDGF) b-receptor but not the PDGF a-receptor. Mol Biol Cell 17: 4846-4855.
82. Katafuchi T, Li AJ, Hirota S, Kitamura Y, Hori T. 2000. Impairment of spatial learning and hippocampal synaptic potentiation inc-kit mutant rats. Learn Mem7:383-392.
83. Kawaguchi N, Horiuchi K, Becherer JD, Toyama Y, Besmer P, Blobel CP. 2007. Different ADAMs have distinct influences on Kit ligand processing: Phorbol-ester-stimulated ec-todomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. J Cell Sci 120: 943-952.
84. Kimura Y, Jones N, Kluppel M, Hirashima M, Tachibana K, Cohn JB, Wrana JL, Pawson T, Bernstein A. 2004. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci 101: 6015-6020.
85. Kissel H, Timokhina I, Hardy MP, Rothschild G, Tajima Y, Soares V, Angeles M, Whitlow SR, Manova K, Besmer P. 2000. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J 19: 1312-1326.
86. Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Shani M, Soriano P. 2001. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol Cell 7: 343-354.
87. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Simino-vitch KA. 1998. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 18: 2089-2099.
88. Krampert M, Heldin C-H, Heuchel R.2008. Again-of-func-tion mutation in the PDGFR-b alters the kinetics of injury response in liver and skin. Lab Invest 88: 1204-1214.
89. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T. 1992. Amplification of a-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Oncogene 7: 627-633.
90. Lechleider RJ, Sugimoto S, Bennett AM, Kashishian AS, Cooper JA, Shoelson SE, Walsh CT, Neel BG. 1993. Activation of the SH2-containing phosphotyrosine phospha-tase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor b. J Biol Chem 268: 21478-21481.
91. Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J. 1997. Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 272: 6311-6317.
92. Lennartsson J, Blume-Jensen P, Hermanson M, Pontén E, Carlberg M, Rönnstrand L. 1999. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP ki-nase pathway and c-fos induction. Oncogene 18: 5546-5553.
93. Lennartsson J, Wardega P, Engström U, Hellman U, Heldin C-H. 2006. Alix facilitates the interaction between c-Cbl and platelet-derived growth factor b-receptor and thereby modulates receptor downregulation. J Biol Chem 281: 39152-39158.
94. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. 1994. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887.
95. Li L, Heldin C-H, Heldin P. 2006. Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. J Biol Chem 281: 26512-26519.
96. Lidén A, Berg A, Nedrebø T, Reed RK, Rubin K. 2006. Platelet-derived growth factor BB-mediated normalization of dermal interstitial fluid pressure after mast cell degranu-lation depends on b3 but not b1 integrins. Circulation Res 98: 635-641.
97. Lindahl P, Johansson BR, Levéen P, Betsholtz C. 1997. Peri-cyte loss and microaneurysm formation in PDGF-B-de-ficient mice. Science 277: 242-245.
98. Lindahl P, Karlsson L, Hellström M, Gebre-Medhin S, Wil-letts K, Heath JK, Betsholtz C. 1997. Alveogenesis failure in PDGF-A-deficient mice is coupled to lack of distal spreading of alveolar smooth muscle cell progenitors during lung development. Development 124: 3943-3953.
99. Lindahl P, Hellström M, Kalén M, Karlsson L, Pekny M, Pekna M, Soriano P, Betsholtz C. 1998. Paracrine PDGF-B/PDGF-Rb signaling controls mesangial cell development in kidney glomeruli. Development 125: 3313-3322.
100. Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW. 2004. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46: 283-291.
101. Lokker NA, O'Hare JP, Barsoumian A, Tomlinson JE, Ra-makrishnan V, Fretto LJ, Giese NA. 1997. Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies. J Biol Chem 272: 33037-33044.
102. Longley BJ, Tyrrell L, Ma Y, Williams DA, Halaban R, Lang-ley K, Lu HS, Schechter NM. 1997. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci 94: 9017-9021.
103. Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK. 2002. Platelet-derived growth factor (PDGF)-induced tyrosine phosphoryla-tion of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem 277: 15499-15506.
104. Lyford GL, He CL, Soffer E, Hull TL, Strong SA, Senagore AJ, Burgart LJ, Young-Fadok T, Szurszewski JH, Farrugia G. 2002. Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 51: 496-501.
105. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butter-field JH, McMahon G, Longley BJ. 2002. The c-KITmu-tation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744.
106. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE. 2001. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor b receptor in chronic myelomonocytic leukemia. Blood 98: 2518-2525.
107. Masson K, Heiss E, Band H, Rönnstrand L. 2006. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem J 399: 5-67.
108. {thorn} exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 20: 8352-8363.
109. Minami A, Mizutani K, Waseda M, Kajita M, Miyata M, Ikeda W, Takai Y. 2010. Necl-5/PVR enhances PDGF-induced attraction of growing microtubules to the plasma membrane of the leading edge of moving NIH3T3 cells. Genes Cells 15: 1123-1135.
110. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H. 1999. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell prolifera-tion-A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 274: 16619-16628.
111. Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, Broxmayer HE. 1994. Ligand-dependent polyubiquitina-tion of c-kit product: A possible mechanism of receptor down regulation in M107e cells. Blood 83: 137-145.
112. Miyazawa K, Bäckström G, Leppänen O, Persson C, Wernstedt C, Hellman U, Heldin C-H, Ostman A. 1998. Role of immunoglobulin-like domains 2-4 of the platelet-derived growth factor a-receptor in ligand-receptor complex assembly. J Biol Chem 273: 25495-25502.
113. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, Nowakowski J, Kassel DB, Cronin CN, McRee DE. 2003. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278: 31461-31464.
114. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP. 2004. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-31663.
115. Mori S, Heldin C-H, Claesson-Welsh L. 1992. Ligand-in-duced polyubiquitination of the platelet-derived growth factor b-receptor. J Biol Chem 267: 6429-6434.
116. Motro B, Wojtowicz JM, Bernstein A, van der Kooy D. 1996. Steel mutant mice are deficient in hippocampal learning but not long-term potentiation. Proc Natl Acad Sci 93: 1808-1813.
117. O'Brien KP, Seroussi E, Dal Cin P, Sciot R, Mandahl N, Fletcher JA, Turc-Carel C, Dumanski JP. 1998. Various regions within the a-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in der-matofibrosarcomas and giant-cell fibroblastomas. Gene Chrom Cancer 23: 187-193.
118. Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, StockW. 2011. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: Are we there yet? Semin Oncol 38: 196-214.
119. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, Kina T, Nakauchi H. 1991. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174: 63-71.
120. Ohlsson R, Falck P, Hellström M, Lindahl P, Boström H, Franklin G, Ährlund-Richter L, Pollard J, Soriano P, Besholtz C. 1999. PDGFB regulates the development of the labyrinthine layer of the mouse fetal placenta. Dev Biol 212: 124-136.
121. Oliveira SH, Lukacs NW. 2003. Stem cell factor: A hemo-poietic cytokine with important targets in asthma. Curr Drug Targets Inflamm Allergy 2: 313-318.
122. Olson LE, Soriano P. 2009. Increased PDGFRa activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 16: 303-313.
123. Omura T, Heldin C-H, Ostman A. 1997. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. J Biol Chem 272: 12676-12682.
124. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, et al. 2003. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102: 3093-3096.
125. Paulson RF, Vesely S, Siminovitch KA, Bernstein A. 1996. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phospha-tase Shp1. Nat Genet 13: 309-315.
126. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Ostman A. 2003. PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443.
127. Pietras K, Pahler J, Bergers G, Hanahan D. 2008. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5: e19.
128. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J, Paetau A, Joensuu H, Nupponen NN. 2006. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4: 927-934.
129. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DW, Bernstein A, Pawson T. 1991. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J 10: 2451-2459.
130. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. 1992. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339: 23-25.
131. Rodt SA, Ahlén K, Berg A, Rubin K, Reed RK. 1996. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495: 193-200.
132. Rolny C, Nilsson I, Magnusson P, Armulik A, Jakobsson L, Wentzel P, Lindblom P, Norlin J, Betsholtz C, Heuchel R, et al. 2006. Platelet-derived growth factor receptor-b promotes early endothelial cell differentiation. Blood 108: 1877-1886.
133. Ross R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809.
134. Rossi P, Dolci S, Sette C, Geremia R. 2003. Molecular mechanisms utilized by alternative c-kit gene products in the control of spermatogonial proliferation and sperm-mediated egg activation. Andrologia 35: 71-78.
135. Russell MR, Jamieson WL, Dolloff NG, Fatatis A. 2009. The a-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28: 412-421.
136. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. 2001. Receptor heterodimerization: Essential mechanism for platelet-derived growthfactor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 21: 6387-6394.
137. Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, Griffin JD. 1997. Steel factor induces tyrosine phos-phorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem 272: 10248-10253.
138. Schmees C, Villaseñor R, Zheng W, Ma H, Zerial M, Heldin C-H, Hellberg C. 2012. Macropinocytosis of the PDGF b-receptor promotes fibroblast transformation by H-RasG12V. Mol Biol Cell 23: 2571-2582.
139. Schneller M, Vuori K, Ruoslahti E. 1997. Avb3 integrin associates with activated insulin and PDGFb receptors and potentiates the biological activity of PDGF. EMBO J 16: 5600-5607.
140. Sette C, Bevilacqua A, Bianchini A, Mangia F, Geremia R, Rossi P. 1997. Parthenogenetic activation of mouse eggs by microinjection of a truncated c-kit tyrosine kinase present in spermatozoa. Development 124: 2267-2274.
141. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, He X. 2010. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci 107: 11307-11312.
142. Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin C-H, Dumanski JP, Ostman A. 1999. The dermatofibrosarcoma protuberans-associated collagen type Ia1/platelet-derived growth factor (PDGF) B-chain fusion genegeneratesatransforming protein that is processed to functional PDGF-BB. Cancer Res 59: 3719-3723.
143. Simon M-P, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre J-M, Terrier-Lacombe M-J, Mandahl N, Craver RD, Blin N, et al. 1997. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 15: 95-98.
144. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD. 2000. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 59: 495-503.
145. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879.
146. Soriano P. 1994. Abnormal kidney development and hema-tological disorders in PDGF b-receptor mutant mice. Genes Dev 8: 1888-1896.
147. Soriano P. 1997. The PDGFa receptor is required for neural crest cell development and for normal patterning of the somites. Development 124: 2691-2700.
148. Sorkin A, Westermark B, Heldin C-H, Claesson-Welsh L. 1991. Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF b-receptor. J Cell Biol 112: 469-478.
149. Soroceanu L, Akhavan A, Cobbs CS. 2008. Platelet-derived growth factor-a receptor activation is required for human cytomegalovirus infection. Nature 455: 391-395.
150. Spritz RA. 1994. Molecular basis of human piebaldism. J Invest Dermatol 103: 137S-140S.
151. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J. 2006. Activation of FIP1L1-PDGFRa requires disruption of the juxtamem-brane domain of PDGFRa and is FIP1L1-independent. Proc Natl Acad Sci 103: 8078-8083.
152. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. 1995. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270: 296-299.
153. Sundberg C, Rubin K. 1996. Stimulation of b1 integrins on fibroblasts induces PDGF independent tyrosine phos-phorylation of PDGF b-receptors. J Cell Biol 132: 741-752.
154. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. 2006. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 25: 910-920.
155. Tallquist MD, Soriano P. 2003. Cell autonomous requirement for PDGFRa in populations of cranial and cardiac neural crest cells. Development 130: 507-518.
156. Tallquist MD, Weismann KE, Hellstrom M, Soriano P. 2000. Early myotome specification regulates PDGFA expression and axial skeleton development. Development 127: 5059-5070.
157. Theisen CS, Wahl JK III, Johnson KR, Wheelock MJ. 2007. NHERF links the N-cadherin/catenin complex to the platelet-derived growth factor receptor to modulate the actin cytoskeleton and regulate cell motility. Mol Biol Cell 18: 1220-1232.
158. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithe-lial-mesenchymal transitions in development and disease. Cell 139: 871-890.
159. Timokhina I, Kissel H, Stella G, Besmer P. 1998. Kit signaling through PI3-kinase and Src kinase pathways: An essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 17: 6250-6262.
160. Toffalini F, Hellberg C, Demoulin J-B. 2010. Critical role of the platelet-derived growth factor receptor (PDGFR) b transmembrane domain in the TEL-PDGFRb cytosolic oncoprotein. J Biol Chem 285: 12268-12278.
161. Ueda S, Mizuki M, Ikeda H, Tsujimura T, Matsumura I, Nakano K, Daino H, Honda Zi Z, Sonoyama J, Shi-bayama H, et al. 2002. Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemo-taxis: Contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration. Blood 99: 3342-3349.
162. Ustun C, DeRemer DL, Akin C. 2011. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 35: 1143-1152.
163. Van den Akker NM, Winkel LC, Nisancioglu MH, Maas S, Wisse LJ, Armulik A, Poelmann RE, Lie-Venema H, Betsholtz C, Gittenberger-de Groot AC. 2008. PDGF-B signaling is important for murine cardiac development: Its role in developing atrioventricular valves, coronaries, and cardiac innervation. Dev Dyn 237: 494-503.
164. Wang L, Vargas H, French SW. 2000. Cellular origin of gastrointestinal stromal tumors: A study of 27 cases. Arch Pathol Lab Med 124: 1471-1475.
165. Wang Y, Pennock SD, Chen X, Kazlauskas A, Wang Z. 2004. Platelet-derived growth factor receptor-mediated signal transduction from endosomes. J Biol Chem 279: 8038-8046.
166. Ward SM, Burns AJ, Torihashi S, Harney SC, Sanders KM. 1995. Impaired development of interstitial cells and intestinal electrical rhythmicity insteel mutants.Am J Phys-iol 269: C1577-C1585.
167. Wehrle-Haller B. 2003. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 16: 287-296.
168. Wisniewski D, Strife A, Clarkson B. 1996. C-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. Leukemia 10: 1436-1442.
169. Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL Jr. 2004. Imatinib mesylate efficiently achieves therapeutic intratumorconcentrationsinvivo but has limited activity in a xenograft model ofsmall cell lung cancer. Clin Cancer Res 10: 3528-3534.
170. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ. 2004. Platelet-derived growth factor regulates oligoden-drocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 25: 252-262.
171. Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge SA, Ashman LK, Rönnstrand L. 2003. Src family kinases are involved in the differential signaling from two splice forms of c-Kit. J Biol Chem 278: 9159-9166.
172. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745-757.
173. Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F. 2001. A role of PDGFRa in basal cell carcinoma proliferation. Proc Natl Acad Sci 98: 9255-9259.
174. Xu X, Bringas P Jr, Soriano P, Chai Y. 2005. PDGFR-a signaling is critical for tooth cusp and palate morphogenesis. Dev Dyn 232: 75-84.
175. Yang Y, Yuzawa S, Schlessinger J. 2008. Contacts between membrane proximal regions of the PDGF receptor ecto-domain are required for receptor activation but not for receptordimerization.ProcNatlAcadSci 105:7681-7686.
176. 0-kinase, and protein kinase C. J Biol Chem 269: 31991-31998.
177. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schles-singer J. 2007. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130: 323-334.
178. Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, Li SS, Rönn-strand L, Knapp S, Bullock AN, Flores-Morales A. 2011. Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem 286: 480-490.
179. Zeng S, Xu Z, Lipkowitz S, Longley JB. 2005. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105: 226-232.
180. Zhang Z, Zhang R, Joachimiak A, Schlessinger J, Kong XP. 2000. Crystal structure of human stem cell factor: Implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci 97: 7732-7737.
181. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P. 2002. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Gene Chromosome Canc 34: 48-57.